Heart failure & cardiomyopathiesMeta-analysis
Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure
- Pooled analysis of 3 population-based cohort studies
- ARIC, DHS and MESA pooled
Authors' conclusion
A higher prevalence of malignant LVH may in part explain the higher risk of HF among blacks versus whites.
Study context
- Population
- Participants without prevalent CVD
- Participants
- 15,710 participants · 3 cohorts
- Comparison
- Malignant left ventricular hypertrophy (LVH) vs LVH with normal biomarkers vs no LVH
- Outcome
- Incident HF
- Follow-up
- 10-year follow-up
Pooled result
As reported in the abstract
Each group vs no LVHAdjusted hazard ratio (95% CI)
Malignant LVH
2.8(2.1–3.5)
LVH, normal biomarkers
0.9(0.6–1.5)
- Heart failure (HF) overall
- 512 (3.3%)
Further pooled results
Incident HF by race/sex · 10-year follow-up
- Black men
- 5.2%
- White men
- 3.8%
- Black women
- 3.2%
- White women
- 2.2%
Prevalence of malignant LVH by race
- 3-fold higher among black men and women vs white men and women
Mediation: excess HF hazard explained by higher malignant LVH prevalence in blacks
- Black men
- 33%
- Black women
- 11%
Malignant LVH at baseline among black men who developed HF
- Proportion with malignant LVH
- 30.8%
- Population attributable fraction
- 0.21
- Intermediate and similar in black women and white men; lowest in white women
Original publication
Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure. Circulation. Published 14 January 2020. doi:10.1161/circulationaha.119.043628
Summarised from the published abstract; every number is checked against it